02083nas a2200361   4500000000100000008004100001260001300042653001000055653002600065653002000091653001100111653002200122653001100144653002100155653001200176653002400188653002500212653000900237653001800246653002400264653002500288653003100313100001100344700001500355700001300370700001300383245009800396856004100494300001100535490000700546520115400553022001401707       1999                            d  c1999 Dec10aAdult10aAntibodies, Bacterial10aContact Tracing10aFemale10aFollow-Up Studies10aHumans10aImmunoglobulin G10aleprosy10aLeprosy, Borderline10aLeprosy, lepromatous10aMale10aMycobacterium10aMycobacterium bovis10aMycobacterium leprae10aMycobacterium tuberculosis1 aRada E1 aAranzazu N1 aUlrich M1 aConvit J00aSerologic response to mycobacterial proteins in hansen's patients during multidrug treatment.  uhttp://ila.ilsl.br/pdfs/v67n4a07.pdf  a414-210 v673 a<p>Humoral immune responses were studied in 24 leprosy patients treated with multidrug therapy (MDT) and 16 contacts. The patients were monitored for 2 to 3 years with repeated determination of IgG antibody levels directed to different mycobacterial proteins (Mycobacterium tuberculosis, Mt70; M. bovis, Mb65; M. leprae, Ml36, 28, 18, 10 kDa, and the complete protein M. leprae extract, MLSA). All recombinant antigens were used at 5 micrograms/ml concentration and the complete soluble M. leprae extract at 2 micrograms/ml. The results shown in this study reveal a clear decline in IgG antibodies directed toward mycobacterial proteins in the 12 multibacillary (MB) patients when they were submitted to MDT. Initially we found strong reactivity toward complete cytosolic protein and M. leprae membrane protein. The most reactive recombinant proteins in MB patients were Ml10, Ml36, Mt70 kDa and, finally, Ml18 kDa when compared to the paucibacillary (PB) group. After treatment was completed all lepromatous and borderline lepromatous patients showed low or undetectable levels as compared with their initial values before starting treatment.</p>
  a0148-916X